Skip to content
OpenCapital
Get started

Ocular Therapeutix OCUL Derivative Liabilities (Non-Current)

Derivative Liabilities (Non-Current) at other companies

PVL
Palvella TherapeuticsPVLA
$2.16M+25.3%

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.21B+58.2%
Enterprise value$1.63B+40.8%
P/S42.6×+19.1×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's derivative liabilities (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ocular Therapeutix's derivative liabilities (non-current)?
Ocular Therapeutix (OCUL) reported derivative liabilities (non-current) of $12.07M in Q1 2026.
How has Ocular Therapeutix's derivative liabilities (non-current) changed year-over-year?
Ocular Therapeutix's derivative liabilities (non-current) decreased by 12.9% year-over-year, from $13.85M to $12.07M.
What is the long-term trend for Ocular Therapeutix's derivative liabilities (non-current)?
Over 5 years (2020 to 2025), Ocular Therapeutix's derivative liabilities (non-current) has grown at a -32.4% compound annual growth rate (CAGR), from $98.31M to $13.9M.
What does derivative liabilities (non-current) mean?
This metric represents the fair value of financial instruments classified as liabilities that are expected to be settled beyond a twelve-month period. These instruments often arise from complex financing arrangements, such as warrants or embedded conversion features in debt, which fluctuate based on underlying equity prices or other market variables. Monitoring this balance is essential for assessing long-term financial risk and potential future dilution or cash outflows associated with non-operating financial obligations.